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Background
Percutaneous coronary intervention (PCI) involving drug-eluting stents is increas-
ingly used to treat complex coronary artery disease, although coronary-artery bypass 
grafting (CABG) has been the treatment of choice historically. Our trial compared 
PCI and CABG for treating patients with previously untreated three-vessel or left 
main coronary artery disease (or both).
Methods
We randomly assigned 1800 patients with three-vessel or left main coronary artery 
disease to undergo CABG or PCI (in a 1:1 ratio). For all these patients, the local car-
diac surgeon and interventional cardiologist determined that equivalent anatomical 
revascularization could be achieved with either treatment. A noninferiority compari-
son of the two groups was performed for the primary end point — a major adverse 
cardiac or cerebrovascular event (i.e., death from any cause, stroke, myocardial in-
farction, or repeat revascularization) during the 12-month period after randomiza-
tion. Patients for whom only one of the two treatment options would be beneficial, 
because of anatomical features or clinical conditions, were entered into a parallel, 
nested CABG or PCI registry.
Results
Most of the preoperative characteristics were similar in the two groups. Rates of 
major adverse cardiac or cerebrovascular events at 12 months were significantly high-
er in the PCI group (17.8%, vs. 12.4% for CABG; P = 0.002), in large part because of 
an increased rate of repeat revascularization (13.5% vs. 5.9%, P<0.001); as a result, 
the criterion for noninferiority was not met. At 12 months, the rates of death and 
myocardial infarction were similar between the two groups; stroke was significantly 
more likely to occur with CABG (2.2%, vs. 0.6% with PCI; P = 0.003).
Conclusions
CABG remains the standard of care for patients with three-vessel or left main coronary 
artery disease, since the use of CABG, as compared with PCI, resulted in lower rates of 
the combined end point of major adverse cardiac or cerebrovascular events at 1 year. 
(ClinicalTrials.gov number, NCT00114972.)
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Coronary-artery bypass grafting (CABG) was introduced in 1968 and rap-idly became the standard of care for symp-
tomatic patients with coronary artery disease.1 Ad-
vances in coronary surgery (e.g., off-pump CABG, 
smaller incisions, enhanced myocardial preserva-
tion, use of arterial conduits, and improved post-
operative care) have reduced morbidity, mortality, 
and rates of graft occlusion.2-6
Percutaneous coronary intervention (PCI) was 
introduced in 1977.7 Experience with this ap-
proach, coupled with improved technology, has 
made it possible to treat increasingly complex le-
sions and patients with a history of clinically sig-
nificant cardiac disease, risk factors for coronary 
artery disease, coexisting conditions, or anatomi-
cal risk factors.8,9 Several trials comparing PCI in-
volving bare-metal stents with CABG in patients 
with multivessel disease (e.g., the Arterial Revas-
cularization Therapies Study Part I [ARTS I], the 
Medicine, Angioplasty, or Surgery Study for Multi-
vessel Coronary Artery Disease [MASS II; Current 
Controlled Trials number, ISRCTN66068876], 
the Argentine Randomized Study of Coronary 
Angioplasty with Stenting versus Coronary By-
pass Surgery in Patients with Multiple Vessel 
Disease [ERACI-II], and the Angina with Ex-
tremely Serious Operative Mortality Evaluation 
[AWESOME]) showed similar survival rates but 
higher revascularization rates among patients 
with bare-metal stents at 5 years. Others have 
shown a significant long-term survival advan-
tage with surgery (e.g., the Stent or Surgery [SOS] 
study).10-12 Studies comparing PCI involving drug-
eluting stents with CABG have generally been 
smaller and nonrandomized.13-24
Data from randomized, controlled trials of 
drug-eluting stents as compared with bare-metal 
stents have shown significant reductions in the 
rate of repeat intervention, with similar rates of 
death and myocardial infarction.25 These improve-
ments have led to expanded use of PCI in pa-
tients with complex coronary anatomical features, 
though most randomized trials comparing drug-
eluting stents and bare-metal stents excluded such 
patients. According to current guidelines,26 CABG 
remains the treatment of choice for patients with 
severe coronary artery disease, including those 
with left main coronary artery disease and those 
with three-vessel disease. There is a lack of data 
from adequately powered randomized trials of PCI 
in such patients. Thus, PCI is being performed in 
this group without adequate support from evi-
dence-based medicine and randomized clinical 
trials.27
In the Synergy between PCI with Taxus and 
Cardiac Surgery (SYNTAX) trial, we assessed the 
optimal revascularization strategy for patients with 
previously untreated three-vessel or left main coro-
nary artery disease and defined the populations 
of patients for whom only one revascularization 
method will be effective.
Me thods
Study Design
The SYNTAX trial is a prospective, clinical trial 
conducted in 85 sites and approved by the insti-
tutional review board at each participating cen-
ter. The study had an “all-comers” design involv-
ing the consecutive enrollment of all eligible 
patients with three-vessel or left main coronary 
artery disease at sites in 17 countries in Europe 
and the United States. The study design has been 
described previously.28 Criteria for study and reg-
istry enrollment and outcome data are described 
in the Supplementary Appendix. The authors de-
signed the study, as part of their role on the steer-
ing committee, in collaboration with the sponsor, 
Boston Scientific. The sponsor was involved in 
collection and source verification of the data, with 
oversight by an independent clinical events com-
mittee. The sponsor’s biostatisticians performed 
the analyses; however, data analyses were verified 
independently by a statistician on the data and 
safety monitoring committee. The authors wrote 
the manuscript and vouch for the completeness 
and accuracy of the data gathering and analysis.
Selection and Randomization of Patients
A local interventional cardiologist and cardiac sur-
geon at each site prospectively evaluated eligible 
patients with previously untreated three-vessel cor-
onary disease and those with left main coronary 
artery disease (alone or with one-, two-, or three-
vessel disease). Inclusion and exclusion criteria are 
listed in the Methods section of the Supplemen-
tary Appendix. Patients in whom it was deter-
mined that equivalent anatomical revasculariza-
tion could be achieved with either CABG or PCI 
involving Taxus Express paclitaxel-eluting stents 
(Boston Scientific) were randomly assigned to un-
dergo one of the two treatment options by means 
of an interactive voice-responding system. Ran-
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domization was stratified at each site according 
to the presence or absence of left main coronary 
artery disease and medically treated diabetes (dia-
betes for which the patient was receiving oral hy-
poglycemic agents or insulin at the time of en-
rollment). Patients for whom only one treatment 
option was suitable were entered into a parallel, 
nested registry: the PCI registry for CABG-ineligi-
ble patients and the CABG registry for PCI-ineli-
gible patients.
All diagnostic angiograms and electrocardio-
grams were reviewed by staff at an independent 
core laboratory (Cardialysis, Rotterdam, the Neth-
erlands) who were unaware of the treatment as-
signments. Diagnostic angiograms were scored, 
according to the SYNTAX score algorithm,29 at the 
site and at the core laboratory. In addition, staff 
at an independent central chemistry laboratory 
(Covance, Indianapolis and Geneva) who were un-
aware of treatment assignments assessed selected 
variables.
The institutional review board at each site ap-
proved the protocol, and all patients provided 
written informed consent. The protocol and con-
sent forms were consistent with the Food and 
Drug Administration’s Guidance for Industry E6 
Good Clinical Practice, the Declaration of Helsin-
ki, the International Conference on Harmonisa-
tion, and all local regulations, as appropriate.
Revascularization and Pharmacologic 
Treatment
Patients were treated with the intention of achiev-
ing complete revascularization of all vessels at 
least 1.5 mm in diameter with stenosis of 50% or 
more, as identified by the local interventional car-
diologist and cardiac surgeon. The surgical tech-
nique for CABG, the approaches used for stent 
implantation, and the postprocedure medication 
regimen were chosen according to local clinical 
practice. In patients who underwent PCI, antiplate-
let medication was prescribed on the basis of the 
directions for use of the Taxus Express stent and 
local clinical practice. In most centers, thienopyri-
dines were continued even after 6 months, with 
71.1% of patients receiving them at 12 months. 
Aspirin was prescribed indefinitely for all patients 
who underwent randomization. Use of the stan-
dard of postintervention care was recommended.30 
Procedural details are described in the Methods 
section of the Supplementary Appendix.
Primary End Point
The primary clinical end point was a composite of 
major adverse cardiac and cerebrovascular events 
(i.e., death from any cause, stroke, myocardial in-
farction, or repeat revascularization) throughout 
the 12-month period after randomization. An in-
dependent clinical events committee (including 
cardiologists, cardiac surgeons, and a neurologist; 
see the list in the Supplementary Appendix) adju-
dicated all primary clinical end points, staged 
procedures, and cases in which the sternum was 
reopened.
Statistical Analysis
The primary analysis was a noninferiority com-
parison of the two treatments for the primary 
end point of adverse binary cardiac or cerebro-
vascular events in all patients who underwent ran-
domization (on an intention-to-treat basis). If the 
one-sided 95% upper confidence limit for the dif-
ference was less than the prespecified delta value 
(6.6%), PCI with the drug-eluting stents would be 
considered to be noninferior to CABG in the over-
all randomized cohort. The noninferiority margin 
was based on historical data (see the Methods sec-
tion in the Supplementary Appendix). We calcu-
lated the means (±SD) for continuous variables in 
each of the two groups and compared them us-
ing Student’s t-test. Binary variables are reported 
as counts and percentages, and differences be-
tween the two groups were assessed by means of 
the chi-square or Fisher’s exact test. Cumulative 
event rates were estimated by means of the Kap-
lan–Meier method. In addition, the 12-month 
rates of major adverse cardiac or cerebrovascular 
events were analyzed on the basis of the SYNTAX 
score and compared with the use of a chi-square 
test. The SYNTAX score reflects a comprehensive 
anatomical assessment, with higher scores indi-
cating more complex coronary disease; a low score 
was defined as ≤22, an intermediate score as 23 
to 32, and a high score as ≥33 (see the Supple-
mentary Appendix for details).
R esult s
Study Participants
From March 2005 through April 2007, a total of 
4337 patients with previously untreated three-vessel 
or left main coronary artery disease (or both) were 
screened (Fig. 1). After consideration by the local 
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interventional cardiologist and cardiac surgeon 
and after written informed consent was obtained, 
3075 patients (70.9%) were included in the study. 
Of these, 1800 patients were randomly assigned to 
undergo CABG (897 patients) or PCI with drug-
eluting stents (903 patients) at sites in the United 
States (245 patients) and in Europe (1555 patients). 
The reasons for exclusion of the remaining 1262 
patients are listed in Figure 1. Only one treatment 
option was suitable in 1275 patients (29.4%), who 
were enrolled in the nested registry for CABG (1077 
patients) or PCI (198 patients).
Patients in the two groups were well balanced 
with regard to most of the baseline demographic 
and clinical characteristics (Table 1). The propor-
tion of patients with blood pressure of 130/80 
mm Hg or higher was significantly larger in the 
PCI group. The numbers of current smokers, pa-
tients with elevated triglyceride levels (≥150 mg per 
deciliter [1.7 mmol per liter]), and patients with 
reduced high-density lipoprotein cholesterol levels 
(<40 mg per deciliter [1.0 mmol per liter] for men 
or <50 mg per deciliter [1.3 mmol per liter] for 
women) were higher in the CABG group. A total 
of 38.8% of patients in the CABG group and 39.5% 
of those in the PCI group had left main coronary 
artery disease, with or without additional diseased 
vessels. Approximately 25% of patients had medi-
cally treated diabetes, of whom about one third 
required insulin. Moreover, nearly half the pa-
tients (45.8%) met the criteria for the metabolic 
syndrome.33 More than 20% of patients in both 
groups were considered to be at high surgical 
risk, on the basis of a European System for Car-
diac Operative Risk Evaluation (euroSCORE)31 
value of 6 or more (24.9% in the CABG group 
and 24.7% in the PCI group, P = 0.94) and a Par-
sonnet score32 of 15 or more (20.2% and 20.5%, 
respectively; P = 0.87).
Overall, more than 4 clinically significant coro-
nary lesions were treated per patient (mean, 4.4 for 
CABG and 4.3 for PCI); among all patients in both 
groups, total occlusion was identified in 23.1%, 
and 72.8% had a bifurcation lesion (Table 1). These 
results, together with other lesion characteristics, 
resulted in an average raw SYNTAX score of 29.1 
in the CABG group and 28.4 in the PCI group 
(P = 0.19) (Table 1).
The length of time between randomization and 
performance of the study procedure, the duration 
of the procedure, and the duration of the post-
procedural hospital stay were significantly great-
er with CABG than with PCI (Table 1). A higher 
proportion of patients had complete revascular-
ization after CABG than after PCI (63.2% vs. 
56.7%, P = 0.005). Medical management at dis-
charge differed between the CABG and PCI groups: 
patients who underwent CABG received less phar-
macologic treatment, whereas those who under-
went PCI were consistently treated with antiplate-
let medications (Table 2). In the CABG group, 
off-pump surgery was performed in 15.0% of pa-
tients, one or more arterial grafts were used in 
97.3% of patients, and an average of 2.8 conduits 
and 3.2 distal anastomoses per patient were per-
formed. In the PCI group, 14.1% of patients un-
derwent staged procedures, 63.1% had at least one 
bifurcation or trifurcation treated, more than four 
stents on average were implanted per patient, and 
a third of patients had placement of stents with 
a total length of more than 100 mm.
A greater proportion of patients in the CABG 
registry had characteristics of severe lesions — in-
cluding large proportions of patients with total 
occlusion (56.4%), bifurcation (80.8%), lesions that 
were more than 20 mm in length (31.5%), and 
heavy calcification (32.7%) — than in either ran-
domized group or the PCI registry (Table 2 in the 
Supplementary Appendix). Together with other 
anatomical characteristics, these features resulted 
in an average raw SYNTAX score of 37.8±13.3 
among the patients in the CABG registry (Table 2 
in the Supplementary Appendix). In contrast, the 
prevalence of cardiac risk factors and the preva-
lence of coexisting conditions were increased 
among patients enrolled in the PCI registry. A total 
of 30.2% of these patients had diabetes, 40.4% had 
previously had a myocardial infarction, 19.3% had 
a diagnosis of chronic obstructive pulmonary dis-
ease, 14.1% had a history of transient ischemic 
attacks or stroke, and 4.7% were dependent on 
pacemakers — leading to average surgical scores 
that were higher than in the other groups of pa-
tients (euroSCORE value, 5.8±3.1; and Parsonnet 
score, 14.4±9.5) (Table 2 in the Supplementary Ap-
pendix).
Primary Outcome
Preprocedural rates of major adverse cardiac or 
cerebrovascular events were low and did not differ 
significantly between the two groups (0.9% in the 
CABG group and 0.3% in the PCI group, P = 0.13) 
(Table 6 in the Supplementary Appendix), as was 
the case for in-hospital rates. The preprocedural 
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rates of two of the individual components of the 
primary outcome, stroke and myocardial infarc-
tion, were similar in the two groups (Table 2 in 
the Supplementary Appendix). At 12 months, the 
incidence of major adverse cardiac or cerebrovas-
cular events was lower in the CABG group (12.4%) 
than in the PCI group (17.8%, P = 0.002) (Fig. 2 
and Table 3). Thus, the absolute difference in the 
12-month rate of major adverse cardiac or cere-
brovascular events between the two groups was 
5.5 percentage points, with an upper 95% confi-
dence interval of 8.3 percentage points. The results 
of an as-treated analysis were similar: the 12-month 
rate of major adverse cardiac or cerebrovascular 
events was 12.3% with CABG and 17.6% with PCI 
(P = 0.002).
39p6
4337 Patients were assessed
for eligibility
1262 Were ineligible
408 Had a treatment preference
306 Declined to participate after providing 
informed consent, or the referring 
physician declined to accept the
patient’s consent
210 Met exclusion criteria
194 Declined to participate before providing 
informed consent
79 Had other reason
51 Underwent medical treatment
14 Declined to undergo revascularization
1800 Underwent randomization
48 Did not have data
analyzed
40 Were withdrawn
8 Were lost to 
follow-up
12 Did not have data
analyzed
7 Were withdrawn
4 Were lost to follow-up
1 Was not treated 
because inclusion
criteria were not met
897 Were assigned to 
undergo CABG
16 Underwent PCI
25 Underwent neither 
CABG nor PCI
903 Were assigned to 
undergo PCI
11 Underwent CABG
6 Underwent neither 
PCI nor CABG
849 (94.6%) Had data
analyzed
891 (98.7%) Had data
analyzed
1077 Were enrolled
in CABG registry
198 Were enrolled
in PCI registry
1275 Were eligible only for enroll-
ment  in a parallel, nested registry
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Figure 1. Enrollment and Randomization of Patients with Previously Untreated Three-Vessel or Left Main Coronary Artery Disease  
in the SYNTAX Trial.
The trial used an “all-comers” design. Exclusion criteria were previous intervention, acute myocardial infarction, and concomitant sur-
gery. Patients meeting either of the first two exclusion criteria were, according to the trial design, excluded without consultation of the 
local interventional cardiologist and cardiac surgeon. The need for concomitant surgery was discussed with the local interventional car-
diologist and cardiac surgeon. Data for patients who were assigned to one treatment but underwent the other and for those who did 
not undergo either revascularization procedure were analyzed in an intention-to-treat manner. CABG denotes coronary-artery bypass 
grafting, and PCI percutaneous coronary intervention.
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Table 1. Baseline Characteristics of the Patients, According to Study Group.*
Characteristic PCI (N = 903) CABG (N = 897) P Value
Age — yr 65.2±9.7 65.0±9.8 0.55
Male sex — % 76.4 78.9 0.20
Body-mass index† 28.1±4.8 27.9±4.5 0.37
Medically treated diabetes — %‡
Any 25.6 24.6 0.64
Requiring insulin 9.9 10.4 0.72
Metabolic syndrome — % 46.0 45.5 0.86
Current smoker — % 18.5 22.0 0.06
Previous myocardial infarction — % 31.9 33.8 0.39
Previous stroke — % 3.9 4.8 0.33
Previous transient ischemic attack — % 4.3 5.1 0.46
Blood pressure ≥130/85 mm Hg — % 68.9 64.0 0.03
Congestive heart failure — % 4.0 5.3 0.18
Carotid artery disease — % 8.1 8.4 0.83
Hyperlipidemia — % 78.7 77.2 0.44
Triglycerides ≥150 mg/dl (1.7 mmol/liter) — % 32.3 38.7 0.007
HDL cholesterol <40 mg/dl (1.0 mmol/liter) 
for men or <50 mg/dl (1.3 mmol/liter) for 
women — %
46.2 52.5 0.01
Angina — %
Stable 56.9 57.2 0.91
Unstable 28.9 28.0 0.66
Ejection fraction <30% — % 1.3 2.5 0.08
euroSCORE value 3.8±2.6 3.8±2.7 0.78
Parsonnet score 8.5±7.0 8.4±6.8 0.76
SYNTAX score 28.4±11.5 29.1±11.4 0.19
No. of lesions 4.3±1.8 4.4±1.8 0.44
Total occlusion — % 24.2 22.2 0.33
Bifurcation — % 72.4 73.3 0.67
Time to procedure — days 6.9±13.0 17.4±28.0 <0.001
Procedure duration — hr 1.7±0.9 3.4±1.1 <0.001
Postprocedural hospital stay — days 3.4±4.5 9.5±8.0 <0.001
Complete revascularization — % 56.7 63.2 0.005
* Plus–minus values are means ±SD. Data are given for the intention-to-treat population. P values, the average SYNTAX 
score, the average number of lesions, and the percentages of patients with total occlusion and bifurcation were calcu-
lated at the core laboratory. The European System for Cardiac Operative Risk Evaluation (euroSCORE) value could 
range from 0 to 18, with increasing values reflecting a higher predicted operative mortality.31  The Parsonnet score 
could range from 0 to 47, with increasing values reflecting a higher predicted in-hospital mortality.32 The SYNTAX score 
reflects a comprehensive anatomical assessment, with scores ranging from 0 to 83 and higher scores indicating more 
complex coronary disease (see the Supplementary Appendix for details). CABG denotes coronary-artery bypass grafting, 
HDL high-density lipoprotein, and PCI percutaneous coronary intervention.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Medically treated diabetes was defined as diabetes for which the patient was receiving oral hypoglycemic agents or in-
sulin at the time of enrollment. 
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In the intention-to-treat population, 19 patients 
would need to be treated with CABG to avoid the 
primary outcome in 1 patient; the numbers needed 
to treat to avoid specific components of the out-
come were 14 for revascularization, 119 for death, 
and 71 for myocardial infarction. The number 
needed to treat with PCI to avoid stroke in 1 pa-
tient was 60.
Secondary Outcome
The rate of repeat revascularization at 12 months 
was significantly higher among patients in the 
PCI group than among those in the CABG group 
(13.5% vs. 5.9%, P<0.001) (Table 3). Most patients 
who underwent repeat revascularization were treat-
ed with PCI rather than CABG. The rate of stroke 
was significantly higher with CABG than with PCI 
at 12 months, even though the two groups were 
well balanced with regard to carotid artery dis-
ease and other risk factors for stroke (Table 3). At 
12 months, the two groups had similar rates of 
death from any cause or myocardial infarction 
and of the combined end point of death from any 
cause, stroke, or myocardial infarction (Table 3). 
The rate of death from cardiac causes was greater 
with PCI than with CABG (3.7% vs. 2.1%, P = 0.05); 
the rate of death from noncardiac causes, although 
not significant, was higher with CABG (1.4% vs. 
0.7%, P = 0.13). The 12-month rates of symptom-
atic graft occlusion (in the CABG group) and stent 
thrombosis (in the PCI group) were similar (P = 0.89) 
(Table 3).
Outcomes According to the SYNTAX Score
In the CABG group, the binary 12-month rates of 
major adverse cardiac or cerebrovascular events 
were similar among patients with low SYNTAX 
scores (0 to 22, 14.7%), those with intermediate 
scores (23 to 32, 12.0%), and those with high scores 
(≥33, 10.9%) (Fig. 3). In contrast, in the PCI group, 
the rate of major adverse cardiac or cerebrovascu-
lar events was significantly increased among pa-
tients with high SYNTAX scores (23.4%) as com-
pared with those with low scores (13.6%) or 
intermediate scores (16.7%) (P = 0.002 for high vs. 
low scores; P = 0.04 for high vs. intermediate scores) 
(Fig. 3). There was a significant interaction be-
tween SYNTAX score and treatment group (P = 0.01); 
patients with low or intermediate scores in the 
CABG group and in the PCI group had similar 
rates of major adverse cardiac or cerebrovascular 
events, whereas among patients with high scores, 
the event rate was significantly increased in the 
PCI group (Fig. 3).
Outcomes in Subgroups
The subgroups of patients with left main or three-
vessel coronary artery disease were prespecified, 
and the study had a statistical power of 80% for 
each subgroup. However, the overarching statis-
tical test was a noninferiority assessment of data 
from all patients with either left main coronary 
artery disease or three-vessel coronary disease (or 
both). Since noninferiority was not proven in this 
Table 2. Cardiac-Related Medications Given after the Study Procedure.*
Medication PCI CABG P Value
percent
Any 98.9 98.6 0.62
Aspirin
At discharge 96.3 88.5 <0.001
1 Mo after procedure 93.5 85.4 <0.001
6 Mo after randomization 93.2 82.7 <0.001
12 Mo after randomization 91.2 84.3 <0.001
Thienopyridine
At discharge 96.8 19.5 <0.001
1 Mo after procedure 95.5 18.4 <0.001
6 Mo after randomization 91.3 16.1 <0.001
12 Mo after randomization 71.1 15.0 <0.001
Any antiplatelet drug
At discharge 97.0 23.7 <0.001
1 Mo after procedure 95.8 21.2 <0.001
6 Mo after randomization 91.4 18.4 <0.001
12 Mo after randomization 72.8 17.2 <0.001
Nonthienopyridine antiplatelet drug 1.9 4.8 <0.001
Warfarin derivative 2.6 7.1 <0.001
Statin 86.7 74.5 <0.001
Beta-blocker 81.3 78.6 0.17
ACE inhibitor 55.1 44.6 <0.001
Calcium-channel blocker 25.8 18.4 <0.001
Angiotensin II–receptor antagonist 13.3 7.0 <0.001
Amiodarone 1.5 12.8 <0.001
H2-receptor blocker 14.5 21.7 <0.001
* Percentages are from the intention-to-treat analysis. ACE denotes angiotensin-
converting enzyme, CABG coronary-artery bypass grafting, and PCI percutane-
ous coronary intervention.
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cohort, specific information for each subgroup is 
of an observational nature and is hypothesis gen-
erating. The 12-month rate of major adverse car-
diac or cerebrovascular events among patients with 
left main coronary artery disease was similar in 
the CABG and PCI groups (13.7% and 15.8%, 
respectively; P = 0.44). Although the rate of repeat 
revascularization among patients with left main 
coronary artery disease was significantly higher 
in the PCI group (11.8%, vs. 6.5% in the CABG 
group; P = 0.02), this result was offset by a signifi-
cantly higher rate of stroke in the CABG sub-
group of patients with left main coronary artery 
disease (2.7%, vs. 0.3% in the corresponding PCI 
subgroup; P = 0.01). A total of 36.6% of patients 
with left main coronary artery disease also had 
three-vessel disease. A post hoc analysis of the 
rates of major adverse cardiac or cerebrovascular 
events in the subgroups of patients with left main 
coronary artery disease revealed a higher rate 
among those who also had two- or three-vessel 
disease than among those with left main coro-
nary artery disease alone or in combination with 
one-vessel disease (Fig. 6 in the Supplementary Ap-
pendix).
The 12-month rate of major adverse cardiac or 
cerebrovascular events among patients with three-
vessel disease in the absence of left main coronary 
artery disease was significantly increased in the 
PCI group as compared with the CABG group 
(19.2% vs. 11.5%, P<0.001) (Fig. 6 in the Supple-
mentary Appendix), as was the rate of repeat revas-
cularization (14.6% vs. 5.5%, P<0.001). The rate 
of death from any cause, stroke, or myocardial 
infarction in this subgroup was similar with PCI 
and CABG (8.0% and 6.6%, respectively; P = 0.39).
Comparisons of data for the cohort with left 
main coronary artery disease and the cohort with 
three-vessel disease showed that the cohort with 
three-vessel disease had higher rates of previous 
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Figure 2. Rates of Outcomes among the Study Patients, According to Treatment Group.
Kaplan–Meier curves are shown for the percutaneous coronary intervention (PCI) group and the coronary-artery by-
pass grafting (CABG) group for death from any cause (Panel A); death, stroke, or myocardial infarction (MI) (Panel 
B); repeat revascularization (Panel C); and the composite primary end point of major adverse cardiac or cerebrovas-
cular events (Panel D). The two groups had similar rates of death from any cause (relative risk with PCI vs. CABG, 
1.24; 95% confidence interval [CI], 0.78 to 1.98) and rates of death from any cause, stroke, or MI (relative risk with 
PCI vs. CABG, 1.00; 95% CI, 0.72 to 1.38). In contrast, the rate of repeat revascularization was significantly in-
creased with PCI (relative risk, 2.29; 95% CI, 1.67 to 3.14), as was the overall rate of major adverse cardiac or cere-
brovascular events (relative risk, 1.44; 95% CI, 1.15 to 1.81). The I bars indicate 1.5 SE. Relative risks were calculated 
from the binary rates. P values were calculated with the use of the chi-square test.
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myocardial infarction, diabetes, poor left ventricu-
lar ejection fraction, and lesions with adverse char-
acteristics (lesions that were totally occluded, bi-
furcated, or long). In addition, the cohort with 
three-vessel disease had increased numbers of 
treated vessels and lesions per patient.
Discussion
The SYNTAX trial was designed to compare cur-
rent surgical and percutaneous techniques in pa-
tients with three-vessel or left main coronary ar-
tery disease (or both). For the primary end point, 
the 12-month rate of major adverse cardiac or cere-
brovascular events, the noninferiority of PCI as 
compared with CABG was not demonstrated; 
CABG proved to be superior. Therefore, the find-
ings with regard to components of the primary end 
point and subgroup analyses can only be consid-
ered as hypothesis-generating. Rates of death and 
myocardial infarction at 1 year were similar be-
tween patients who underwent CABG and those 
who underwent PCI with drug-eluting stents, 
whereas the rate of stroke was increased in the 
CABG group and the rate of repeat revasculariza-
tion was increased in the PCI group.
Rates of repeat revascularization at 12 months 
were low in the PCI group, given the high rates 
of several known predictors of restenosis: lesions 
characterized by bifurcation or trifurcation (>80%), 
multivessel disease (>60%), diabetes (>25%), and 
lesions that were long (>20 mm in length, 20%) 
or totally occluded (>25%). This rate of repeat 
revascularization is lower than the rates reported 
Table 3. Clinical End Points Occurring in the Hospital or after Discharge, According to Study Group.*
Variable PCI CABG P Value
Relative Risk with 
PCI (95% CI)
no./total no. (%)
Major adverse cardiac or  
cerebrovascular event
In hospital 39/896 (4.4) 47/870 (5.4) 0.31 0.81 (0.53–1.22)
30 Days after procedure 54/895 (6.0) 45/866 (5.2) 0.45 1.16 (0.79–1.71)
6 Mo after randomization 111/893 (12.4) 85/860 (9.9) 0.09 1.26 (0.96–1.64)
12 Mo after randomization 159/891 (17.8) 105/849 (12.4) 0.002 1.44 (1.15–1.81)
Death, stroke, or MI 68/891 (7.6) 65/849 (7.7) 0.98 1.00 (0.72–1.38)
Death 39/891 (4.4) 30/849 (3.5) 0.37 1.24 (0.78–1.98)
From cardiac causes 33/891 (3.7) 18/849 (2.1) 0.05 1.75 (0.99–3.08)
From cardiovascular causes 1/891 (0.1) 3/849 (0.4) 0.36† 0.32 (0.03–3.05)
From noncardiovascular causes 5/891 (0.6) 9/849 (1.1) 0.24 0.53 (0.18–1.57)
Stroke 5/891 (0.6) 19/849 (2.2) 0.003 0.25 (0.09–0.67)
MI 43/891 (4.8) 28/849 (3.3) 0.11 1.46 (0.92–2.33)
Repeat revascularization‡ 120/891 (13.5) 50/849 (5.9) <0.001 2.29 (1.67–3.14)
CABG 25/891 (2.8) 11/849 (1.3) 0.03 2.17 (1.07–4.37)
PCI 102/891 (11.4) 40/849 (4.7) <0.001 2.43 (1.71–3.46)
Graft occlusion or stent thrombosis§ 28/848 (3.3) 27/784 (3.4) 0.89 0.96 (0.57–1.62)
Acute (at ≤1 day) 2/896 (0.2) 3/870 (0.3) 0.68† 0.65 (0.11–3.86)
Early (within 2–30 days) 18/893 (2.0) 3/868 (0.3) 0.001 5.83 (1.72–19.73)
Late (within 31–365 days) 9/874 (1.0) 21/854 (2.5) 0.02 0.42 (0.19–0.91)
* Percentages are from the intention-to-treat analysis. P values were calculated with the use of the chi-square test, unless 
otherwise noted. CABG denotes coronary-artery bypass grafting, MI myocardial infarction, and PCI percutaneous coro-
nary intervention.
† The P value was calculated with the use of Fisher’s exact test.
‡ One patient randomly assigned to undergo CABG and seven patients randomly assigned to undergo PCI underwent 
both repeat PCI and repeat CABG.
§ Stent thrombosis was adjudicated according to the protocol definition.
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in previous comparative trials involving patients 
with less-complex clinical profiles and lesions.10 
The increase in the rate of repeat revasculariza-
tion with PCI as compared with CABG did not 
appear to translate into a significant overall in-
crease in the rate of death or myocardial infarc-
tion, although longer-term follow-up is needed. 
The risk of repeat revascularization after PCI needs 
to be balanced against the invasiveness of CABG 
and the risk of stroke, as previously reported in 
a meta-analysis of 23 studies comparing CABG 
and PCI, in which procedure-related strokes were 
found to be more common after CABG (in 1.2% 
of patients, vs. 0.6% of those undergoing PCI; 
P<0.001), without a concomitant decrease in sur-
vival.34
Recently, concern has been expressed about the 
possibility of an increased risk of late stent throm-
bosis with drug-eluting stents. In the SYNTAX trial, 
most cases of stent thrombosis occurred within 
30 days after the procedure, and the 12-month rate 
of stent thrombosis in the PCI group was similar 
to the rate of symptomatic graft occlusion in the 
CABG group. However, as described in the litera-
ture, stent thrombosis often has more serious 
consequences for patients (rate of death, ap-
proximately 30%; rate of myocardial infarction, 
>60%)35,36 than does graft occlusion, which often 
results only in angina leading to revascularization.
The use of antiplatelet medication was high 
among patients in the PCI group (with 71.1% 
receiving a thienopyridine at 12 months). There 
was an imbalance between the two groups with 
regard to general medical management apart from 
thienopyridine use. Thienopyridine therapy was 
not mandated beyond 6 months in the PCI group, 
since the study was designed to compare current 
CABG and PCI practices, including medication 
regimens. The low rate of stroke among patients 
who underwent PCI may have resulted from the 
use of highly effective dual-antiplatelet therapy, 
which prevents thromboembolic events; additional 
treatment with antiplatelet drugs might there-
fore benefit patients undergoing CABG. In addi-
tion, more patients in the CABG group than in 
the PCI group declined to participate after pro-
viding consent; in general, this imbalance was due 
to the greater invasiveness of CABG.
The SYNTAX score was designed to predict out-
comes related to anatomical characteristics and, 
to a lesser extent, the functional risk of occlusion 
for any segment of the coronary-artery bed (as re-
flected by the Leaman score37). In our study, the 
raw SYNTAX score was predictive of outcomes in 
patients who underwent PCI. In particular, among 
patients in the PCI group with high SYNTAX 
scores, not only was the overall rate of major ad-
verse cardiac or cerebrovascular events signifi-
cantly increased, but also the rate of the compos-
ite components of death, stroke, and myocardial 
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Figure 3. Rates of Major Adverse Cardiac or Cerebrovascular Events  
among the Study Patients, According to Treatment Group and SYNTAX 
Score Category.
Kaplan–Meier curves are shown for the percutaneous coronary intervention 
(PCI) group and the coronary-artery bypass grafting (CABG) group for ma-
jor adverse cardiac or cerebrovascular events at 12 months. The 12-month 
event rates were similar between the two treatment groups for patients 
with low SYNTAX scores (0 to 22) (Panel A) or intermediate SYNTAX 
scores (23 to 32) (Panel B). Among patients with high SYNTAX scores  
(≥33, indicating the most complex disease), those in the PCI group had a 
significantly higher event rate at 12 months than those in the CABG group. 
SYNTAX scores were calculated at the core laboratory. The I bars indicate 
1.5 SE. P values were calculated with the use of the chi-square test.
Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF DEBRECEN on April 29, 2010 . 
PCI vs. CABG for Severe Coronary Artery Disease
n engl j med 360;10 nejm.org march 5, 2009 971
infarction was slightly raised (11.9%, vs. 7.6% in 
the CABG group; P = 0.08). This finding suggests 
that a percutaneous approach should be avoided 
in patients with high SYNTAX scores. Similar 
results were reported after the stratification of 
patients with three-vessel disease in the ARTS II 
registry.38 Retrospective analysis of the ability of 
the SYNTAX score to predict outcome is currently 
being performed and is anticipated to be used to 
evaluate the relative weight of the individual score 
components. Additional validation of the score in 
other populations of patients is also needed. Out-
comes in the surgical group of our randomized 
cohort were not influenced by the SYNTAX score.
The completeness of revascularization (i.e., 
whether all identified lesions were treated) was 
determined after the procedure by the investiga-
tor. The rate of complete revascularization was 
lower in both treatment groups in our study than 
in previous studies.14,15,21,23,39 This result is most 
likely due to a different definition of completeness 
of treatment used in the earlier trials and the more 
complex anatomical characteristics of the patients 
in our trial.
Although our study provides important infor-
mation about current treatment of coronary artery 
disease, there are limitations. First, the 12-month 
follow-up period may not be sufficient to reflect 
the true long-term effect of CABG as compared 
with PCI with drug-eluting stents on cardiac-relat-
ed health. However, our early results in terms of 
major adverse cardiac or cerebrovascular events 
are similar to those of a meta-analysis34 of trials 
comparing CABG and PCI with predominantly 
bare-metal stents. The meta-analysis showed that 
the rate of major adverse cardiac or cerebrovas-
cular events was lower with CABG than with PCI 
and that patients who underwent CABG had fewer 
repeat revascularization procedures than patients 
who underwent PCI. After 5 years of follow-up, the 
meta-analysis did not show any significant differ-
ences in rates of survival between the CABG and 
PCI groups,34 although other studies have shown 
differences in mortality.10-12 
Second, the use of medication differed between 
the groups in our study, reflecting variations in 
standard care of patients between the two treat-
ment groups. Third, more patients withdrew, af-
ter randomization, from the CABG group than 
from the PCI group. Fourth, although random-
ization was conducted in a blinded manner, with 
clinicians and participants unaware of future 
treatment assignments, it was not possible to blind 
the performance of the treatment. Finally, the 
definition of myocardial infarction was based on 
a surgical definition (the finding of a new Q-wave 
on electrocardiography, in association with a value 
for the creatine kinase MB fraction that was five 
times the upper limit of the normal range), which 
may have resulted in less severe cases of myocar-
dial infarction being overlooked.
In conclusion, the results of our trial show that 
CABG, as compared with PCI, is associated with 
a lower rate of major adverse cardiac or cerebro-
vascular events at 1 year among patients with 
three-vessel or left main coronary artery disease 
(or both) and should therefore remain the stan-
dard of care for such patients.
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